SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Gold/Mining/Energy : Daytrading Canadian stocks in Realtime
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Rocket Red who wrote (53339)9/2/2001 9:47:16 PM
From: bigbuk  Read Replies (1) of 62348
 
VERY BIG GRIN :))))))))))))))))

love those gapdowns-- hope iright :)))

Using a competitor's analysis, Alan Abelson of Barron's took aim at Med-Design Corp. (MEDC: news, chart, profile) over the weekend, praising the CEO of Retractable Technologies (RVP: news, chart, profile) for his critique of Wall Street's kind treatment of his rival. Thomas Shaw, Abelson wrote, aptly pointed that much of the fuss over Med-Design is tied to the company's patents for various automated retraction syringes -- including technologies that have tenuous sales prospects at best. And even if they do make it to market, Shaw said, slow FDA approval and limited patent life will generate only a small fraction of the tens of millions they have helped tack on to the company's market cap. Shares in Med-Design closed down $1.90, or better than 7 percent, to $23.70 Friday while Retractable tacked on 20 cents to $4.90.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News